Moreover, circulating Tph cells were higher in patients with pSS with lymphadenopathy (11.06 ± 8.86% vs. 4.74 ± 2.01%, p = 0.002), cutaneous involvement (14.27 ± 14.91% vs. 6.52 ± 4.19%, p = 0.003), pulmonary involvement (10.91 ± 10.7% vs. 6.26 ± 4.16%, p = 0.02), hematologic disorder (neutropenia, lymphopenia, anemia, or thrombocytopenia) (8.84 ± 7.39% vs. 3.83 ± 1.80%, p = 0.001), and biological changes (hypocomplementemia or hypergammaglobulinemia) (8.50 ± 7.38% vs. 4.20 ± 1.84%, p = 0.001) (data not shown), compared to patients with pSS who had no relevant symptoms. This evidence concerns the gene TPH1 and hematologic disorder.